Seqirus Pty Ltd – FDA 483, Jun 6, 2025
An FDA inspection of Seqirus Pty Ltd in Parkville, Australia, revealed significant deficiencies in their vaccine manufacturing operations. Observations included inadequate investigations into persistent fungal contamination in drug substance production, structural issues with a building used for component storage, and critical data integrity and user access control failures for manufacturing equipment. These findings indicate a need for comprehensive corrective actions to ensure product quality and data reliability.
ID · 96c86fab-f499-45c0-bee1-19ea35d6462a
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.